**Supplementary tables**

**Supplementary table 1:** The interaction between the probability of a major osteoporotic fracture and treatment for the two doses of teriparatide (20 and 40μg) alone and in combination. Interaction is expressed as the β-coefficient and standard deviation (SD).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **FRAX model** | **Outcome** | **Placebo vs 40+20 µg** |  | **Placebo vs. 20 µg** |  | **Placebo vs. 40 µg** |
|  |  | **β** | **SD** | **p=** |  | **β** | **SD** | **p=** |  | **β** | **SD** | **p=** |
| Without BMD | Any non-vertebral fracture | -0.0094 | 0.018 | >0.30 |  | -0.0016 | 0.021 | >0.30 |  | -0.0185 | 0.022 | >0.30 |
|  | Osteoporotic non-vertebral fracture | 0.0144 | 0.023 | >0.30 |  | 0.0290 | 0.027 | 0.28 |  | -0.00102 | 0.029 | >0.30 |
|  | Morphometric vertebral fracture | 0.0362 | 0.019 | 0.061 |  | 0.0436 | 0.077 | >0.30 |  | 0.0292 | 0.025 | 0.24 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| With BMD | Any non-vertebral fracture | -0.0087 | 0.017 | >0.30 |  | -0.0075 | 0.020 | >0.30 |  | -0.0107 | 0.022 | >0.30 |
|  | Osteoporotic non-vertebral fracture | 0.0276 | 0.023 | 0.23 |  | 0.0327 | 0.026 | 0.21 |  | 0.0229 | 0.028 | >0.30 |
|  | Morphometric vertebral fracture | 0.0101 | 0.019 | >0.30 |  | 0.0041 | 0.022 | >0.30 |  | 0.0187 | 0.025 | >0.30 |

**Supplementary table 2:**  Hazard ratio between treatments (teriparatide vs. placebo) for risk of any non-vertebral fracture at different values of baseline 10-year hip fracture probability (%).

|  |  |  |  |
| --- | --- | --- | --- |
|  | **FRAX: hip without BMD**  |  | **FRAX: hip with BMD**  |
| **Percentile** | **10 year probability** | **HR** | **95% CI** |  | **10 year probability** | **HR** | **95% CI** |
| 10th  | 1.7% | 0.65 | 0.39-1.10 |  | 1.4% | 0.63 | 0.38-1.06 |
| 25th  | 3.0% | 0.65 | 0.40-1.04 |  | 2.9% | 0.63 | 0.39-1.01 |
| 50th  | 5.5% | 0.64 | 0.42-0.95 |  | 5.6% | 0.62 | 0.41-0.93 |
| 75th  | 10.2% | 0.62 | 0.42-0.91 |  | 10.2% | 0.60 | 0.41- 0.88 |
| 90th  | 15.6% | 0.59 | 0.35-1.02 |  | 16.3% | 0.58 | 0.35- 0.96 |

**Supplementary table 3:** Hazard ratio between treatments (teriparatide vs. placebo) for morphometric vertebral fracture risk at different values of baseline 10-year hip fracture probability (%).

|  |  |  |  |
| --- | --- | --- | --- |
|  | **FRAX-hip without BMD**  |  | **FRAX- hip with BMD**  |
| **Percentile** | **10 year probability** | **HR** | **95% CI** |  | **10 year probability** | **HR** | **95% CI** |
| 10th  | 1.7% | 0.27 | 0.16-0.48 |  | 1.4% | 0.34 | 0.19-0.58 |
| 25th  | 3.0% | 0.28 | 0.17-0.47 |  | 2.9% | 0.33 | 0.20-0.55 |
| 50th  | 5.5% | 0.29 | 0.19-0.46 |  | 5.6% | 0.32 | 0.20-0.50 |
| 75th  | 10.2% | 0.32 | 0.21-0.49 |  | 10.2% | 0.30 | 0.20-0.45 |
| 90th  | 15.6% | 0.36 | 0.20-0.63 |  | 16.3% | 0.27 | 0.16-0.46 |

**Supplementary table 4:** Hazard ratio between treatments (teriparatide vs. placebo) for risk of any low energy non-vertebral fracture at different values of baseline 10-year probability (%) of fracture calculated with inclusion of BMD.

|  |  |  |
| --- | --- | --- |
|  |  | **FRAX: major osteoporotic including BMD**  |
| **Percentile** |  | **10 year probability** | **HR** | **95% CI** |
| 10th  |  | 8.5% | 0.47 | 0.20-1.11 |
| 25th  |  | 12.2% | 0.46 | 0.23-0.95 |
| 50th  |  | 17.6% | 0.45 | 0.25-0.81 |
| 75th  |  | 24.4% | 0.43 | 0.24-0.76 |
| 90th  |  | 32.6% | 0.41 | 0.19-0.86 |